$RXST
Rxsight Inc Stock $rxst

$rxst Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-K Financial Statement

#000095017022003135 Filed on March 08, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021
Revenue	$8.942M	$8.426M	$22.59M
YoY Change	156.66%	71.47%	53.92%
Cost Of Revenue	$5.181M	$5.557M	$18.08M
YoY Change	119.07%	57.24%	39.34%
Gross Profit	$3.761M	$2.869M	$4.517M
YoY Change	236.1%	107.9%	164.93%
Gross Profit Margin	42.06%	34.05%	19.99%
Selling, General & Admin	$13.62M	$11.69M	$32.81M
YoY Change	142.74%	165.89%	116.16%
% of Gross Profit	362.14%	407.32%	726.26%
Research & Development	$6.719M	$5.841M	$24.50M
YoY Change	1.14%	10.83%	11.69%
% of Gross Profit	178.65%	203.59%	542.37%
Depreciation & Amortization	$1.016M	$1.019M	$3.975M
YoY Change	6.05%	-66.69%	3.17%
% of Gross Profit	27.01%	35.52%	88.0%
Operating Expenses	$20.34M	$17.53M	$57.30M
YoY Change	65.98%	81.21%	54.39%
Operating Profit	-$16.58M	-$14.66M	-$52.79M
YoY Change	48.88%	76.77%	49.07%
Interest Expense	$1.060M	-$1.069M	$3.682M
YoY Change	51.86%	124.11%	621.96%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00	$7.735M
YoY Change	-100.0%	-100.0%	-87.72%
Pretax Income	-$17.59M	-$15.73M	-$48.68M
YoY Change	158.78%	-159.82%	-276.17%
Income Tax	-$4.000K	$2.000K	$8.000K
% Of Pretax Income
Net Earnings	-$17.60M	-$15.73M	-$48.69M
YoY Change	158.57%	-159.84%	-276.57%
Net Earnings / Revenue	-196.78%	-186.73%	-215.5%
Basic Earnings Per Share	-$0.64		-$3.57
Diluted Earnings Per Share	-$641.6K	-$572.1K	-$3.57
COMMON SHARES
Basic Shares Outstanding	27.42M	27.35M	13.63M
Diluted Shares Outstanding	27.43M		13.63M

Balance Sheet

Concept	2022 Q1	2021 Q4	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$143.8M	$159.3M	$159.3M
YoY Change	123.43%		131.0%
Cash & Equivalents	$24.13M	$24.36M	$24.36M
Short-Term Investments	$119.7M	$135.0M	$135.0M
Other Short-Term Assets	$3.184M	$4.069M	$4.069M
YoY Change	121.73%		196.57%
Inventory	$8.490M	$8.032M	$8.032M
Prepaid Expenses
Receivables	$5.626M	$4.862M	$4.862M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$161.1M	$176.3M	$176.3M
YoY Change	107.01%	116.31%	116.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.92M	$11.22M	$15.50M
YoY Change	-38.94%	-15.58%	-16.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$132.0K	$114.0K	$925.0K
YoY Change	-76.88%	3.64%	62.0%
Total Long-Term Assets	$15.92M	$16.43M	$16.43M
YoY Change	-13.73%	-14.35%	-14.35%
TOTAL ASSETS
Total Short-Term Assets	$161.1M	$176.3M	$176.3M
Total Long-Term Assets	$15.92M	$16.43M	$16.43M
Total Assets	$177.1M	$192.7M	$192.7M
YoY Change	83.88%	91.43%	91.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.587M	$1.689M	$1.689M
YoY Change	39.01%	48.94%	48.94%
Accrued Expenses	$7.997M	$7.859M	$8.615M
YoY Change	60.81%	88.28%	74.57%
Deferred Revenue		$618.0K
YoY Change		48.2%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$75.00K	$20.00K	$20.00K
YoY Change	226.09%		-25.93%
Total Short-Term Liabilities	$10.66M	$11.08M	$11.08M
YoY Change	55.45%	-4.51%	-4.51%
LONG-TERM LIABILITIES
Long-Term Debt	$39.97M	$39.78M	$39.78M
YoY Change	35.49%		62.78%
Other Long-Term Liabilities	$3.266M	$3.625M	$3.625M
YoY Change	-61.71%		-59.13%
Total Long-Term Liabilities	$43.24M	$43.40M	$43.40M
YoY Change	13.69%		30.31%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.66M	$11.08M	$11.08M
Total Long-Term Liabilities	$43.24M	$43.40M	$43.40M
Total Liabilities	$53.90M	$54.48M	$54.48M
YoY Change	20.07%	21.32%	21.32%
SHAREHOLDERS EQUITY
Retained Earnings	-$496.9M	-$479.3M
YoY Change		11.31%
Common Stock	$27.00K	$27.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$123.2M	$138.2M	$138.2M
YoY Change
Total Liabilities & Shareholders Equity	$177.1M	$192.7M	$192.7M
YoY Change	83.88%	91.43%	91.43%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021
OPERATING ACTIVITIES
Net Income	-$17.60M	-$15.73M	-$48.69M
YoY Change	158.57%	-159.84%	-276.57%
Depreciation, Depletion And Amortization	$1.016M	$1.019M	$3.975M
YoY Change	6.05%	-66.69%	3.17%
Cash From Operating Activities	-$14.99M	-$8.722M	-$44.71M
YoY Change	46.17%	-62.05%	27.0%
INVESTING ACTIVITIES
Capital Expenditures	$370.0K	-$365.0K	$1.940M
YoY Change	-25.7%	-78.42%	-23.59%
Acquisitions
YoY Change
Other Investing Activities	$15.23M	-$34.98M	-$79.97M
YoY Change	1.52%	403.83%	-541.08%
Cash From Investing Activities	$14.86M	-$35.35M	-$81.91M
YoY Change	2.45%	309.38%	-625.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$12.40M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-98.00K	404.0K	137.3M
YoY Change	-101.6%	-98.39%	444.21%
NET CHANGE
Cash From Operating Activities	-14.99M	-8.722M	-44.71M
Cash From Investing Activities	14.86M	-35.35M	-81.91M
Cash From Financing Activities	-98.00K	404.0K	137.3M
Net Change In Cash	-229.0K	-43.66M	10.72M
YoY Change	-102.2%	576.23%	90.52%
FREE CASH FLOW
Cash From Operating Activities	-$14.99M	-$8.722M	-$44.71M
Capital Expenditures	$370.0K	-$365.0K	$1.940M
Free Cash Flow	-$15.36M	-$8.357M	-$46.65M
YoY Change	42.84%	-60.75%	23.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021	rxst	Finance Lease Obligations Incurred FinanceLeaseObligationsIncurred
CY2021Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://rxsight.com/20211231#LeaseLiabilitiesCurrent
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentNet
CY2020	rxst	Reclassification Of Deferred Cost ReclassificationOfDeferredCost
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001111485
CY2020	rxst	Reclassification Of Shares Of Redeemable Common Stock To Common Stock Assumed In Non Cash Investing Or Financing Activity ReclassificationOfSharesOfRedeemableCommonStockToCommonStockAssumedInNonCashInvestingOrFinancingActivity
CY2021	rxst	Accretion To Redemption Value Of Redeemable Preferred Stock And Redeemable Stock Options AccretionToRedemptionValueOfRedeemablePreferredStockAndRedeemableStockOptions
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://rxsight.com/20211231#LeaseLiabilitiesNoncurrent
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://rxsight.com/20211231#LeaseLiabilitiesNoncurrent
CY2020Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://rxsight.com/20211231#LeaseLiabilitiesCurrent
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://rxsight.com/20211231#LeaseLiabilitiesCurrent
CY2020	rxst	Conversion Of Preferred Stock To Common Stock Upon Initial Public Offering ConversionOfPreferredStockToCommonStockUponInitialPublicOffering
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://rxsight.com/20211231#LeaseLiabilitiesNoncurrent
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentNet
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://rxsight.com/20211231#LeaseLiabilitiesCurrent
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://rxsight.com/20211231#LeaseLiabilitiesNoncurrent
CY2020	rxst	Reclassification Of Redeemable Common Stock To Common Stock Options Assumed In Non Cash Investing Or Financing Activity ReclassificationOfRedeemableCommonStockToCommonStockOptionsAssumedInNonCashInvestingOrFinancingActivity
CY2020	rxst	Expiration Of Warrant ExpirationOfWarrant
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-40690
CY2021	dei	Entity Registrant Name EntityRegistrantName	RxSight, Inc.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3268801
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 Columbia
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Aliso Viejo
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92656
CY2021	dei	City Area Code CityAreaCode	949
CY2021	dei	Local Phone Number LocalPhoneNumber	521-7830
CY2021	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value per share
CY2021	dei	Trading Symbol TradingSymbol	RXST
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	Yes
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Public Float EntityPublicFloat	236000000
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27417993
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young, LLP
CY2021	dei	Auditor Location AuditorLocation	Irvine, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24361000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13994000
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	134971000
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	54981000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4862000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2865000
CY2021Q4	us-gaap	Inventory Net InventoryNet	8032000
CY2020Q4	us-gaap	Inventory Net InventoryNet	8288000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4069000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1372000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	176295000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	81500000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11217000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13287000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4284000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5319000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	811000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	461000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	114000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	110000
CY2021Q4	us-gaap	Assets Assets	192721000
CY2020Q4	us-gaap	Assets Assets	100677000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1689000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1134000
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7859000
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	4174000
CY2021Q4	rxst	Warrant Liability WarrantLiability	0
CY2020Q4	rxst	Warrant Liability WarrantLiability	5018000
CY2021Q4	rxst	Lease Liabilities Current LeaseLiabilitiesCurrent	1529000
CY2020Q4	rxst	Lease Liabilities Current LeaseLiabilitiesCurrent	1274000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11077000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11600000
CY2021Q4	rxst	Long Term Warrant Liability LongTermWarrantLiability	0
CY2020Q4	rxst	Long Term Warrant Liability LongTermWarrantLiability	3828000
CY2021Q4	rxst	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	3642000
CY2020Q4	rxst	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	5079000
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	39760000
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	24399000
CY2021Q4	us-gaap	Liabilities Liabilities	54479000
CY2020Q4	us-gaap	Liabilities Liabilities	44906000
CY2021Q4	us-gaap	Redeemable Noncontrolling Interest Equity Common Carrying Amount RedeemableNoncontrollingInterestEquityCommonCarryingAmount	0
CY2020Q4	us-gaap	Redeemable Noncontrolling Interest Equity Common Carrying Amount RedeemableNoncontrollingInterestEquityCommonCarryingAmount	80780000
CY2021Q4	rxst	Temporary Equity Note Receivables Common Stock Issued TemporaryEquityNoteReceivablesCommonStockIssued	0
CY2020Q4	rxst	Temporary Equity Note Receivables Common Stock Issued TemporaryEquityNoteReceivablesCommonStockIssued	-803000
CY2021Q4	rxst	Temporary Equity Redeemable Stock Options TemporaryEquityRedeemableStockOptions	0
CY2020Q4	rxst	Temporary Equity Redeemable Stock Options TemporaryEquityRedeemableStockOptions	53085000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27366746
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27366746
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	27000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	0
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	617511000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	0
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-20000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-479276000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-430588000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	138242000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-430591000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	192721000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	100677000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22593000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14678000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	18076000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	12973000
CY2021	us-gaap	Gross Profit GrossProfit	4517000
CY2020	us-gaap	Gross Profit GrossProfit	1705000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	32805000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15176000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24499000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21934000
CY2020	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	7000
CY2021	us-gaap	Operating Expenses OperatingExpenses	57304000
CY2020	us-gaap	Operating Expenses OperatingExpenses	37117000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-52787000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-35412000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2717000
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-63011000
CY2021	rxst	Expiration Of Warrant ExpirationOfWarrant	-5018000
CY2021	us-gaap	Interest Expense InterestExpense	3682000
CY2020	us-gaap	Interest Expense InterestExpense	510000
CY2021	us-gaap	Interest And Other Income InterestAndOtherIncome	54000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-48680000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	27632000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	57000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-48688000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	27575000
CY2020	rxst	Accretion To Redemption Value Of Redeemable Preferred Stock And Redeemable Stock Options AccretionToRedemptionValueOfRedeemablePreferredStockAndRedeemableStockOptions	-24209000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-48688000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	3366000
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-7000
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-49000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-10000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-17000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-49000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48705000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	27526000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.57
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.91
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.57
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.15
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13625044
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3707207
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13625044
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5532305
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-419809000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4185000
CY2020	rxst	Accretion To Redemption Value Of Redeemable Stock Option AccretionToRedemptionValueOfRedeemableStockOption	1461000
CY2020	rxst	Accretion To Redemption Value Of Redeemable Stocks AccretionToRedemptionValueOfRedeemableStocks	-43954000
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-49000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	27575000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-430591000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	347000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7575000
CY2021	us-gaap	Proceeds From Sale Of Notes Receivable ProceedsFromSaleOfNotesReceivable	136000
CY2021	rxst	Redeemable Common Stock Reclassified Shares RedeemableCommonStockReclassifiedShares	4093995
CY2021	rxst	Common Stock After Reclassification Of Redeemable Common Stock Shares CommonStockAfterReclassificationOfRedeemableCommonStockShares	4093995
CY2021	rxst	Common Stock Issued During Period Value Conversion Of Redeemable Common Stock CommonStockIssuedDuringPeriodValueConversionOfRedeemableCommonStock	86885000
CY2021	rxst	Common Stock Options Issued During Period Value Conversion Of Redeemable Common Stock Options CommonStockOptionsIssuedDuringPeriodValueConversionOfRedeemableCommonStockOptions	47370000
CY2021	rxst	Change In Notes Receivable For Redeemable Common Stock Issued ChangeInNotesReceivableForRedeemableCommonStockIssued	452000
CY2021	rxst	Exercise Of Preferred Stock Warrants Net Of Shares Withheld For Exercise Price ExerciseOfPreferredStockWarrantsNetOfSharesWithheldForExercisePrice	-2011000
CY2021	rxst	Amount Of Settlement Of Fractional Shares AmountOfSettlementOfFractionalShares	11000
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	357202000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12400000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	119582000
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-7000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-10000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-48688000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	138242000
CY2021	us-gaap	Profit Loss ProfitLoss	-48688000
CY2020	us-gaap	Profit Loss ProfitLoss	27575000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3975000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3853000
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	13000
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	159000
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	493000
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	85000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2717000
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-63011000
CY2021	rxst	Gain Loss On Expiration Of Warrant GainLossOnExpirationOfWarrant	5018000
CY2020	rxst	Gain Loss On Expiration Of Warrant GainLossOnExpirationOfWarrant	0
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	30000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	446000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	7575000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	4185000
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	7000
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	2367000
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	238000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1996000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2076000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2111000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1307000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2809000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-180000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	555000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-954000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3683000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3691000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-44708000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-35203000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1940000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2539000
CY2021	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	0
CY2020	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	3000
CY2021	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	80000000
CY2020	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	116000000
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	159967000
CY2020	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	97873000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-81907000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	15591000
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	15000000
CY2020	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	25000000
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	132000
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	687000
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	790000
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	23000
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	119582000
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	27000
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	142000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0
CY2021	rxst	Change In Notes Receivable For Redeemable Common Stock Issued Financing Activities ChangeInNotesReceivableForRedeemableCommonStockIssuedFinancingActivities	575000
CY2020	rxst	Change In Notes Receivable For Redeemable Common Stock Issued Financing Activities ChangeInNotesReceivableForRedeemableCommonStockIssuedFinancingActivities	51000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1554000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	992000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	137342000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25237000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-10000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10717000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5625000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14455000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8830000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25172000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14455000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1269000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	987000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	20000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	61000
CY2021	rxst	Interest Paid On Financing Leases InterestPaidOnFinancingLeases	5000
CY2020	rxst	Interest Paid On Financing Leases InterestPaidOnFinancingLeases	14000
CY2021	rxst	Interest Paid On Term Loan InterestPaidOnTermLoan	3182000
CY2020	rxst	Interest Paid On Term Loan InterestPaidOnTermLoan	411000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	126000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1953000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	48000
CY2021	rxst	Operating Lease Obligations Incurred OperatingLeaseObligationsIncurred	126000
CY2020	rxst	Operating Lease Obligations Incurred OperatingLeaseObligationsIncurred	1953000
CY2020	rxst	Finance Lease Obligations Incurred FinanceLeaseObligationsIncurred	48000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	30000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	40000
CY2020	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	38308000
CY2021	us-gaap	Paid In Kind Interest PaidInKindInterest	28000
CY2020	us-gaap	Paid In Kind Interest PaidInKindInterest	54000
CY2021	rxst	Reclassification From Warrant Liability To Additional Paid In Capital For Warrants Exercised ReclassificationFromWarrantLiabilityToAdditionalPaidInCapitalForWarrantsExercised	1111000
CY2020	rxst	Reclassification From Warrant Liability To Additional Paid In Capital For Warrants Exercised ReclassificationFromWarrantLiabilityToAdditionalPaidInCapitalForWarrantsExercised	24000
CY2021	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	4093995
CY2021	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	4093995
CY2021	rxst	Reclassification Of Shares Of Redeemable Common Stock To Common Stock Assumed In Non Cash Investing Or Financing Activity ReclassificationOfSharesOfRedeemableCommonStockToCommonStockAssumedInNonCashInvestingOrFinancingActivity	87702000
CY2021	rxst	Reclassification Of Redeemable Common Stock To Common Stock Options Assumed In Non Cash Investing Or Financing Activity ReclassificationOfRedeemableCommonStockToCommonStockOptionsAssumedInNonCashInvestingOrFinancingActivity	47370000
CY2021	rxst	Conversion Of Preferred Stock To Common Stock Upon Initial Public Offering ConversionOfPreferredStockToCommonStockUponInitialPublicOffering	357202000
CY2021	rxst	Reclassification Of Deferred Cost ReclassificationOfDeferredCost	3156000
CY2021	rxst	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	2
CY2021Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-10.33
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000
CY2021Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.001
CY2021Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	14725309
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	159300000
CY2021	rxst	Operating Income Loss1 OperatingIncomeLoss1	52800000
CY2020	rxst	Operating Income Loss1 OperatingIncomeLoss1	35400000
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements in conformity with GAAP requires management to make informed estimates, judgments and assumptions that affect the reported amounts in the consolidated financial<br/> statements and disclosures in the accompanying notes as of the date of the accompanying consolidated financial statements. On an on-going basis, management evaluates the most critical estimates and assumptions for continued reasonableness. These estimates and assumptions involve judgments with respect to numerous factors that are difficult to predict. Actual results may differ materially from the estimates used in the preparation of the accompanying consolidated financial statements under different assumptions or conditions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Significant accounting policies</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There have been no significant changes to the accounting policies during the year ended December 31, 2021 as compared to the significant accounting policies described in Note 2 of the “Notes to Consolidated Financial Statements” in the Company’s audited consolidated financial statements included in the Company's prospectus filed with the Securities and Exchange Commission in accordance with Rule 424(b) of the Securities Act on July 29, 2021 in connection with our IPO.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"><br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	9000000
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	2000
CY2021	rxst	Increased Decreased In Restricted Cash IncreasedDecreasedInRestrictedCash	350000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	811000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24361000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13994000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	811000
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	461000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25172000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14455000
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments which potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. The Company’s policy is to invest cash in institutional money market funds and marketable securities of the U.S. government to limit the amount of credit exposure. The Company currently maintains a portfolio of cash equivalents and short-term investments in money market funds and U.S. treasury bills. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. The Company has not experienced material losses on cash equivalents and short-term investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s products require approval from the FDA and foreign regulatory agencies before commercial sales can commence. There can be no assurance that the Company’s products will receive any of these required approvals. The denial or delay of such approvals may have a material adverse impact on the Company’s business and may impact business in the future. In addition, after approval by the FDA, there is still an ongoing risk of adverse events that did not appear during the device approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of our products, product liability and the need to obtain additional financing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to the risks related to the global pandemic associated with COVID-19, including local, state, federal and other world-wide mandates imposed to reduce the spread of the virus which could interrupt or reduce the number of cataract surgeries, limit access to ambulatory surgery centers, doctors’ offices and manufacturing facilities, and the expansion of global lead times, particularly in Europe and Asia, leading to a supply interruption from our suppliers. In addition, the Company is currently experiencing inflation and longer lead times and limited availability in its supply chain for certain components and has continued exposure to price and supply risk related to anticipated purchases of certain commodities, materials and products used in its business.</span></p>
CY2021	rxst	Accounts Receivable Percentage AccountsReceivablePercentage	0.10
CY2020	rxst	Accounts Receivable Percentage AccountsReceivablePercentage	0.35
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	540000
CY2020Q4	us-gaap	Deferred Revenue DeferredRevenue	345000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22593000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14678000
CY2021Q4	rxst	Liability On Uncertain Tax Position LiabilityOnUncertainTaxPosition	0
CY2020Q4	rxst	Liability On Uncertain Tax Position LiabilityOnUncertainTaxPosition	0
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4451000
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5092000
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2828000
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1827000
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	868000
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1685000
CY2021Q4	us-gaap	Inventory Gross InventoryGross	8147000
CY2020Q4	us-gaap	Inventory Gross InventoryGross	8604000
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	115000
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	316000
CY2021Q4	us-gaap	Inventory Net InventoryNet	8032000
CY2020Q4	us-gaap	Inventory Net InventoryNet	8288000
CY2021Q4	us-gaap	Other Inventory Materials Supplies And Merchandise Under Consignment OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment	1800000
CY2020Q4	us-gaap	Other Inventory Materials Supplies And Merchandise Under Consignment OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment	2700000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	27562000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25660000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16345000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12373000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11217000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13287000
CY2021	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	4000000.0
CY2020	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	3900000
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	156361000
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	66803000
CY2020Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	8846000
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	5000000.0
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	8846000
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	71881000
CY2021	rxst	Exercise Of Preferred Stock Warrants ExerciseOfPreferredStockWarrants	-1111000
CY2020	rxst	Exercise Of Preferred Stock Warrants ExerciseOfPreferredStockWarrants	-24000
CY2021	rxst	Expiration Of Common Stock Warrants ExpirationOfCommonStockWarrants	-5018000
CY2020	rxst	Expiration Of Common Stock Warrants ExpirationOfCommonStockWarrants	0
CY2021	rxst	Gain Loss From Changes In Fair Value Of Common Stock Warrant GainLossFromChangesInFairValueOfCommonStockWarrant	0
CY2020	rxst	Gain Loss From Changes In Fair Value Of Common Stock Warrant GainLossFromChangesInFairValueOfCommonStockWarrant	-64628000
CY2021	rxst	Gain Loss From Changes In Fair Value Of Preferred Stock Warrants GainLossFromChangesInFairValueOfPreferredStockWarrants	-2717000
CY2020	rxst	Gain Loss From Changes In Fair Value Of Preferred Stock Warrants GainLossFromChangesInFairValueOfPreferredStockWarrants	1617000
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	8846000
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	5916000
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2943000
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	871000
CY2020Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	745000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	618000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	417000
CY2021Q4	rxst	Accrued Interest Current AccruedInterestCurrent	319000
CY2020Q4	rxst	Accrued Interest Current AccruedInterestCurrent	0
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	135000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	69000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7859000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4174000
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.50
CY2021	us-gaap	Debt Instrument Interest Rate Increase Decrease DebtInstrumentInterestRateIncreaseDecrease	0.0016
CY2021	us-gaap	Debt Instrument Basis Spread On Variable Rate1 DebtInstrumentBasisSpreadOnVariableRate1	0.05
CY2021	us-gaap	Long Term Debt Description LongTermDebtDescription	The Term Loan requires 36 months of interest-only payments, followed by 23-months of amortization. If the Company is in compliance with the Performance to Plan covenant through October 31, 2023, the interest-only period is extended by 12 months, and the amortization period is reduced by 11 months. Payments are due on the first day of each month in arrears. All unpaid amounts under the Term Loan mature on October 1, 2025.
CY2021	us-gaap	Short Term Debt Description ShortTermDebtDescription	As the loan was not fully prepaid by December 31, 2021, the Company became subject to an additional fee (the “Exit Fee”). The fee is 3% of the original draw amount if prepaid between January 1, 2022 and October 31, 2022 ($750,000), 4% if prepaid between November 1, 2022 and October 31, 2023 ($1.0 million) and 5% ($1.25 million) if paid subsequently, including at maturity.
CY2021	rxst	Additional Fee Percentage AdditionalFeePercentage	0.05
CY2021	rxst	Additional Fee Amount AdditionalFeeAmount	1250000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Rolling Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths	0
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo	1739000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree	20870000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour	17391000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive	0
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	40000000
CY2021Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	240000
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	39760000
CY2021	us-gaap	Debt Conversion Original Debt Interest Rate Of Debt DebtConversionOriginalDebtInterestRateOfDebt	0.0925
CY2020	us-gaap	Debt Conversion Original Debt Interest Rate Of Debt DebtConversionOriginalDebtInterestRateOfDebt	0.0925
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	16572792
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	14376272
CY2020Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	196528000
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	353300000
CY2021Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	14850993
CY2020	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	14851007
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6878511
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	19278888
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.637
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.632
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.834
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.974
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.946
CY2020	rxst	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate	0.25
CY2020	rxst	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Life ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife	P1Y1M6D
CY2020	rxst	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend Yield ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield	0.000
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	100261
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.616
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.946
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.006
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.017
CY2021	rxst	Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate	0.010
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.16
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.31
CY2020	rxst	Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate	0.249
CY2021	rxst	Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Life SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife	P6Y1M2D
CY2020	rxst	Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Life SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife	P1Y1M6D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2021	rxst	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend Yield ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield	0.000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2020	rxst	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend Yield ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield	0.000
CY2021	rxst	Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Grant Date Fair Value SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue	15.02
CY2020	rxst	Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Grant Date Fair Value SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGrantDateFairValue	0.81
CY2020	rxst	Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Grant Date Fair Value SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue	0.81
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-48694000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	27577000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	14000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	55000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-48680000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	27632000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	7000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	46000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1000
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	11000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	8000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	57000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-9950000
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-7179000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3241000
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-2642000
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	13191000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	9821000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	57000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	62347000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-13191000
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-9821000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	52127000
CY2021Q4	rxst	Deferred Tax Asset Amortization DeferredTaxAssetAmortization	117000
CY2020Q4	rxst	Deferred Tax Asset Amortization DeferredTaxAssetAmortization	134000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2829000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2297000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7902000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	6663000
CY2021Q4	rxst	Deferred Tax Asset Right Of Use Of Liability DeferredTaxAssetRightOfUseOfLiability	1290000
CY2020Q4	rxst	Deferred Tax Asset Right Of Use Of Liability DeferredTaxAssetRightOfUseOfLiability	1585000
CY2021Q4	rxst	Deferred Tax Asset Depreciation DeferredTaxAssetDepreciation	536000
CY2020Q4	rxst	Deferred Tax Asset Depreciation DeferredTaxAssetDepreciation	298000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1745000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	740000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	76766000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	63844000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	75546000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	62355000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1220000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1489000
CY2021Q4	rxst	Deferred Tax Asset Right Of Use Of Asset DeferredTaxAssetRightOfUseOfAsset	1220000
CY2020Q4	rxst	Deferred Tax Asset Right Of Use Of Asset DeferredTaxAssetRightOfUseOfAsset	1489000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1220000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1489000
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	10223000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5793000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.041
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1989000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.053
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1468000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.026
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-1241000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.047
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-1306000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.014
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-677000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.004
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-122000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.026
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	1252000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.479
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	13204000
CY2021	rxst	Effective Income Tax Rate Reconciliation Limitation And Credit Carry Forwards Subject To Expiration EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration	-0.020
CY2021	rxst	Income Tax Reconciliation Limitation And Credit Carry Forwards Subject To Expiration IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration	-960000
CY2020	rxst	Effective Income Tax Rate Reconciliation Limitation And Credit Carry Forwards Subject To Expiration EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration	0.015
CY2020	rxst	Income Tax Reconciliation Limitation And Credit Carry Forwards Subject To Expiration IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration	-426000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.002
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Other IncomeTaxReconciliationTaxCreditsOther	113000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.005
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Other IncomeTaxReconciliationTaxCreditsOther	127000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.271
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-13189000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.356
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-9821000
CY2021	rxst	Effective Income Tax Reconciliation Tax Credits EffectiveIncomeTaxReconciliationTaxCredits	0.000
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	8000
CY2020	rxst	Effective Income Tax Reconciliation Tax Credits EffectiveIncomeTaxReconciliationTaxCredits	0.001
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	57000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	13200000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	9800000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	270400000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	100200000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	270400000
CY2021Q4	rxst	Federal Operating Loss Carry Forwards Not Expire FederalOperatingLossCarryForwardsNotExpire	154000000.0
CY2021Q4	rxst	Taxable Income Offset Percentage TaxableIncomeOffsetPercentage	0.80
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	100200000
CY2021Q4	rxst	State Operating Loss Carry Forwards Not Expire StateOperatingLossCarryForwardsNotExpire	17800000
CY2021Q4	rxst	Taxable Income Offset Percentage TaxableIncomeOffsetPercentage	0.80
CY2021Q4	rxst	Federal Operating Loss Carry Forwards FederalOperatingLossCarryForwards	7300000
CY2021Q4	rxst	State Operating Loss Carry Forwards StateOperatingLossCarryForwards	7200000
CY2020Q1	rxst	Percent Of Taxable Income Offset In Future PercentOfTaxableIncomeOffsetInFuture	1
CY2021	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	Pursuant to Internal Revenue Code (“IRC”) Sections 382 and 383, annual use of the Company’s net operating loss and R&D credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period.
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2554000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2056000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	459000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	486000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	12000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3013000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2554000
CY2021	us-gaap	Foreign Earnings Repatriated ForeignEarningsRepatriated	0
CY2020	us-gaap	Foreign Earnings Repatriated ForeignEarningsRepatriated	0
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4284000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5319000
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	33000
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	58000
CY2021Q4	rxst	Total Lease Assets TotalLeaseAssets	4317000
CY2020Q4	rxst	Total Lease Assets TotalLeaseAssets	5377000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1509000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1247000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	20000
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	27000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3625000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5042000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	17000
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	37000
CY2021Q4	rxst	Total Lease Liabilities TotalLeaseLiabilities	5171000
CY2020Q4	rxst	Total Lease Liabilities TotalLeaseLiabilities	6353000
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	5000
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	14000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1976000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	23000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1683000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	18000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1456000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	0
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	951000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	79000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6145000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	41000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1011000
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	4000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5134000
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	37000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y2M15D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M19D
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y5M1D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.105
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.105
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.105
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.105
CY2021	us-gaap	Legal Fees LegalFees	0
CY2020	us-gaap	Legal Fees LegalFees	0
CY2021Q3	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.02
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.25
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	228000

Files In Submission

Name	View Source	Status
0000950170-22-003135-index-headers.html	Edgar Link	pending
0000950170-22-003135-index.html	Edgar Link	pending
0000950170-22-003135.txt	Edgar Link	pending
0000950170-22-003135-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
img200300128_0.jpg	Edgar Link	pending
img200300128_1.jpg	Edgar Link	pending
img200300128_2.jpg	Edgar Link	pending
img200300128_3.jpg	Edgar Link	pending
img200300128_4.jpg	Edgar Link	pending
img200300128_5.jpg	Edgar Link	pending
img200300128_6.jpg	Edgar Link	pending
img48968354_0.jpg	Edgar Link	pending
img48968354_1.jpg	Edgar Link	pending
img48968354_2.jpg	Edgar Link	pending
img48968354_3.jpg	Edgar Link	pending
img48968354_4.jpg	Edgar Link	pending
img48968354_5.jpg	Edgar Link	pending
img48968354_6.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rxst-20211231.htm	Edgar Link	pending
rxst-20211231.xsd	Edgar Link	pending
rxst-20211231_cal.xml	Edgar Link	unprocessable
rxst-20211231_def.xml	Edgar Link	unprocessable
rxst-20211231_htm.xml	Edgar Link	completed
rxst-20211231_lab.xml	Edgar Link	unprocessable
rxst-20211231_pre.xml	Edgar Link	unprocessable
rxst-ex10_28.htm	Edgar Link	pending
rxst-ex21_1.htm	Edgar Link	pending
rxst-ex23_1.htm	Edgar Link	pending
rxst-ex31_1.htm	Edgar Link	pending
rxst-ex31_2.htm	Edgar Link	pending
rxst-ex32_1.htm	Edgar Link	pending
rxst-ex32_2.htm	Edgar Link	pending
rxst-ex4_2.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RXST
Rxsight Inc Stock $rxst

2022 Q1 Form 10-K Financial Statement

#000095017022003135 Filed on March 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RXST Rxsight Inc Stock $rxst

2022 Q1 Form 10-K Financial Statement

#000095017022003135 Filed on March 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RXST
Rxsight Inc Stock $rxst